Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 21–22
HOS-108912 · Präparat HOS-093083
21
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's
syndrome and adrenal suppression
have been reported in patients
receiving ritonavir and inhaled or
intranasally administered
fluticasone propionate; this could
also occur with other
corticosteroids metabolised via the
P450 3A pathway e.g. budesonide
and triamcinolone. Consequently,
concomitant administration of
Kaletra and these glucocorticoids
is not recommended unless the
potential benefit of treatment
outweighs the risk of systemic
corticosteroid effects (see section
4.4). A dose reduction of the
glucocorticoid should be
considered with close monitoring
of local and systemic effects or a
switch to a glucocorticoid, which
is not a substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in
case of withdrawal of
glucocorticoids progressive dose
reduction may have to be
performed over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 95f7b89617dc0d65066440c9865de8ccb96b79023be5509ed30cc6b686a9782e · Zeichen 45456–48489 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57–58
HOS-109017 · Präparat HOS-093083
57
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's syndrome
and adrenal suppression have been
reported in patients receiving
ritonavir and inhaled or intranasally
administered fluticasone propionate;
this could also occur with other
corticosteroids metabolised via the
P450 3A pathway e.g. budesonide
and triamcinolone. Consequently,
concomitant administration of Kaletra
and these glucocorticoids is not
recommended unless the potential
benefit of treatment outweighs the
risk of systemic corticosteroid effects
(see section 4.4). A dose reduction of
the glucocorticoid should be
considered with close monitoring of
local and systemic effects or a switch
to a glucocorticoid, which is not a
substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in case
of withdrawal of glucocorticoids
progressive dose reduction may have
to be performed over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Tadalafil Tadalafil: For the treatment of pulmonary
AUC: ↑ 2-fold arterial hypertension:
Due to CYP3A4 inhibition by Co-administration of Kaletra with
lopinavir/ritonavir. sildenafil is contraindicated (see
Sildenafil Sildenafil: section 4.3). Co-administration of
AUC: ↑ 11-fold Kaletra with tadalafil is not
Due to CYP3A inhibition by recommended.
lopinavir/ritonavir.
For erectile dysfunction:
Particular caution must be used when
prescribing sildenafil or tadalafil in
patients receiving Kaletra with
increased monitoring for adverse
events including hypotension,
syncope, visual changes and
prolonged erection (see section 4.4).
When co-administered with Kaletra,
sildenafil doses must not exceed
25 mg in 48 hours and tadalafil doses
must not exceed 10 mg every 72
hours.
Vardenafil Vardenafil: The use of vardenafil with Kaletra is
AUC: ↑ 49-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 51c234e1918855f44c1bb972e14fc32ef0403c1dd2140c6f4cb763ba5bcc0839 · Zeichen 44014–48937 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 92–93
HOS-109093 · Präparat HOS-093083
92
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's
syndrome and adrenal suppression
have been reported in patients
receiving ritonavir and inhaled or
intranasally administered
fluticasone propionate; this could
also occur with other corticosteroids
metabolised via the P450 3A
pathway e.g. budesonide and
triamcinolone. Consequently,
concomitant administration of
Kaletra and these glucocorticoids is
not recommended unless the
potential benefit of treatment
outweighs the risk of systemic
corticosteroid effects (see section
4.4). A dose reduction of the
glucocorticoid should be considered
with close monitoring of local and
systemic effects or a switch to a
glucocorticoid, which is not a
substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in
case of withdrawal of
glucocorticoids progressive dose
reduction may have to be performed
over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 497011109bf2b2d1a0b56b0819ad55285ecfc4baf550264239853c107df5ec09 · Zeichen 44865–47860 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 20–21
HOS-112108 · Präparat HOS-093615
20
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules twice approximately 86% (90% confidence CYP3A4 is not recommended
daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be considered
intranasally administered fluticasone with close monitoring of local and
propionate; this could also occur with systemic effects or a switch to a
other corticosteroids metabolised via the glucocorticoid, which is not a
P450 3A pathway, e.g., budesonide. The substrate for CYP3A4 (e.g.,
effects of high fluticasone systemic beclomethasone). Moreover, in case
exposure on ritonavir plasma levels are yet of withdrawal of glucocorticoids,
unknown. The mechanism of interaction is progressive dose reduction may
CYP3A4 inhibition. have to be performed over a longer
period.
Concomitant use of REYATAZ (with or
without ritonavir) and other Inhaled/Nasal Concomitant use of Inhaled/Nasal
Corticosteroids is expected to produce the Corticosteroids and REYATAZ
same effects. (with or without ritonavir) may
increase plasma concentrations of
Inhaled/Nasal corticosteroids. Use
with caution. Consider alternatives
to Inhaled/Nasal Corticosteroids,
particularly for long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil, and vardenafil are
Patients should be warned about
metabolised by CYP3A4. Co- these possible side effects when
administration with REYATAZ may result
using PDE5 inhibitors for erectile
in increased concentrations of the PDE5
dysfunction with REYATAZ (see
inhibitor and an increase in PDE5-
section 4.4).
Also see PULMONARY
associated adverse events, including
ARTERIAL HYPERTENSION in
hypotension, visual changes, and priapism.
this table for further information
The mechanism of this interaction is
CYP3A4 inhibition. regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is Concomitant use of elagolix
anticipated increase in elagolix exposure in 200 mg twice daily with
the presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than 1 month is
not recommended due to the
potential risk of adverse events
such as bone loss and hepatic
transaminase elevations. Limit
concomitant use of elagolix 150 mg
once daily with REYATAZ (with
or without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 635c8268586ef0a6549f4f61ffc231edde0b1b51942c8c61e4e49a8f50290b2a · Zeichen 55637–61614 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 56–57
HOS-112197 · Präparat HOS-093615
56
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules approximately 86% (90% confidence CYP3A4 is not recommended
twice daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be
intranasally administered fluticasone considered with close
propionate; this could also occur with other monitoring of local and
corticosteroids metabolised via the P450 systemic effects or a switch to
3A pathway, e.g., budesonide. The effects a glucocorticoid, which is not a
of high fluticasone systemic exposure on substrate for CYP3A4 (e.g.,
ritonavir plasma levels are yet unknown. beclomethasone). Moreover, in
The mechanism of interaction is CYP3A4 case of withdrawal of
inhibition. glucocorticoids, progressive
dose reduction may have to be
Concomitant use of REYATAZ (with or performed over a longer
without ritonavir) and other Inhaled/Nasal period.
Corticosteroids is expected to produce the
same effects. Concomitant use of
Inhaled/Nasal Corticosteroids
and REYATAZ (with or
without ritonavir) may increase
plasma concentrations of
Inhaled/Nasal corticosteroids.
Use with caution. Consider
alternatives to Inhaled/Nasal
Corticosteroids, particularly for
long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, Sildenafil, tadalafil, and vardenafil are
Patients should be warned
vardenafil metabolised by CYP3A4. Co- about these possible side
administration with REYATAZ may result
effects when using PDE5
in increased concentrations of the PDE5
inhibitors for erectile
inhibitor and an increase in PDE5-
dysfunction with REYATAZ
associated adverse events, including
(see section 4.4).
Also see PULMONARY
hypotension, visual changes, and priapism.
ARTERIAL
The mechanism of this interaction is
CYP3A4 inhibition. HYPERTENSION in this table
for further information
regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is anticipated Concomitant use of elagolix
increase in elagolix exposure in the 200 mg twice daily with
presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than
1 month is not recommended
due to the potential risk of
adverse events such as bone
loss and hepatic transaminase
elevations. Limit concomitant
use of elagolix 150 mg once
daily with REYATAZ (with or
without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 48a34194fe14fdb331f424e7223a33e7800beb55222a98a47e4c5a5060800d73 · Zeichen 57743–64096 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 22–23
HOS-114854 · Präparat HOS-094169
22
Bupropion 150 mg BID Bupropion Cmax ↓ 51% If the co-administration with
Bupropion AUC ↓ 56% bupropion is judged unavoidable,
this should be done under close
Tipranavir ↔ clinical monitoring for bupropion
efficacy, without exceeding the
The reduction of bupropion recommended dosage, despite the
plasma levels is likely due to observed induction.
induction of CYP2B6 and UGT
activity by RTV
Loperamide 16 mg QD Loperamide Cmax ↓ 61% A pharmacodynamic interaction
Loperamide AUC ↓ 51% study in healthy volunteers
demonstrated that administration
Mechanism unknown of loperamide and Aptivus, co-
administered with low dose
Tipranavir Cmax ↔ ritonavir, does not cause any
Tipranavir AUC ↔ clinically relevant change in the
Tipranavir Cmin ↓ 26% respiratory response to carbon
dioxide. The clinical relevance of
the reduced loperamide plasma
concentration is unknown.
Fluticasone propionate In a clinical study where ritonavir Concomitant administration of
Interaction study 100 mg capsules bid were co- Aptivus, co-administered with
performed only with administered with 50 µg low dose ritonavir, and these
ritonavir intranasal fluticasone propionate glucocorticoids is not
(4 times daily) for 7 days in recommended unless the
healthy subjects, the fluticasone potential benefit of treatment
propionate plasma levels outweighs the risk of systemic
increased significantly, whereas corticosteroid effects (see
the intrinsic cortisol levels section 4.4). A dose reduction of
decreased by approximately 86% the glucocorticoid should be
(90% confidence interval considered with close monitoring
82-89%). Greater effects may be of local and systemic effects or a
expected when fluticasone switch to a glucocorticoid, which
propionate is inhaled. Systemic is not a substrate for CYP3A4
corticosteroid effects including (e.g. beclomethasone). Moreover,
Cushing’s syndrome and adrenal in case of withdrawal of
suppression have been reported in glucocorticoids progressive dose
patients receiving ritonavir and reduction may have to be
inhaled or intranasally performed over a longer period.
administered fluticasone The effects of high fluticasone
propionate; this could also occur systemic exposure on ritonavir
with other corticosteroids plasma levels are as yet
metabolised via the P450 3A unknown.
pathway e.g. budesonide.
It is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in fluticasone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) loperamide (HOS-114855) budesonide (HOS-086332) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 7522c1a17dc381755410649aa6db82293f9c200ad2f0eeed696045d4a966abe6 · Zeichen 60402–64824 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-133968 · Präparat HOS-097520
13
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
GLUCOCORTICOIDS
Corticosteroids
Corticosteroids primarily Interaction not studied with any of Concomitant use of Genvoya and
metabolised by CYP3A (including the components of Genvoya. corticosteroids that are metabolised
betamethasone, budesonide, by CYP3A (e.g. fluticasone
fluticasone, mometasone, Plasma concentrations of these propionate or other inhaled or nasal
prednisone, triamcinolone). medicinal products may be corticosteroids) may increase the
increased when co-administered risk of development of systemic
with Genvoya, resulting in reduced corticosteroid effects, including
serum cortisol concentrations. Cushing’s syndrome and adrenal
suppression.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) betamethasone (HOS-090066) budesonide (HOS-086332) mometasone (HOS-114048) propionate (HOS-108915) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 4acfffdad184917b98d978a921f68a1280a07b1ef57cf90080b742c333a4288d · Zeichen 20863–22145 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-134627 · Präparat HOS-097580
59
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Perphenazine Not studied. Boosted darunavir is A dose decrease may be needed for
Risperidone expected to increase these these drugs when co-administered
Thioridazine antipsychotic plasma with boosted darunavir.
concentrations. (CYP3A, CYP2D6
and/or P-gp inhibition)
Lurasidone Concomitant administration of
Pimozide boosted darunavir and lurasidone,
Sertindole pimozide or sertindole is
contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted darunavir is Clinical monitoring is recommended
Metoprolol expected to increase these β-blocker when co-administering boosted
Timolol plasma concentrations. darunavir with β-blockers. A lower
(CYP2D6 inhibition) dose of the β-blocker should be
considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted darunavir can Clinical monitoring of therapeutic
Diltiazem be expected to increase the plasma and adverse effects is recommended
Felodipine concentrations of calcium channel when these medicines are
Nicardipine blockers. concomitantly administered with
Nifedipine (CYP3A and/or CYP2D6 boosted darunavir.
Verapamil inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study Concomitant use of boosted
metabolised by CYP3A where ritonavir 100 mg capsules darunavir and corticosteroids (all
(including betamethasone, twice daily were co-administered routes of administration) that are
budesonide, fluticasone, with 50 μg intranasal fluticasone metabolised by CYP3A may increase
mometasone, prednisone, propionate (4 times daily) for 7 the risk of development of systemic
triamcinolone) days in healthy subjects, fluticasone corticosteroid effects, including
propionate plasma concentrations Cushing’s syndrome and adrenal
increased significantly, whereas the suppression.
intrinsic cortisol levels decreased
by approximately 86% (90% CI 82- Co-administration with CYP3A-
89%). Greater effects may be metabolised corticosteroids is not
expected when fluticasone is recommended unless the potential
inhaled. Systemic corticosteroid benefit to the patient outweighs the
effects including Cushing's risk, in which case patients should be
syndrome and adrenal suppression monitored for systemic corticosteroid
have been reported in patients effects.
receiving ritonavir and inhaled or
intranasally administered Alternative corticosteroids which are
fluticasone. The effects of high less dependent on CYP3A
fluticasone systemic exposure on metabolism
ritonavir plasma levels are e.g. beclomethasone should be
unknown. considered, particularly for long term
use.
Other corticosteroids: interaction
not studied. Plasma concentrations
of these medicinal products may be
increased when co-administered
with boosted darunavir, resulting in
reduced serum cortisol
concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. with boosted darunavir.
(CYP3A induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 5be93392fc9daddc5a4bddcaf5177effda2055057fdf350b6c14c2d3c31e17fc · Zeichen 49576–54404 im Abschnitt
Wechselwirkungen · Seffalair Spiromax
Seffalair Spiromax 12.75 micrograms/100 micrograms inhalation powder Seffalair Spiromax 12.75 micrograms/202 micrograms inhalation powder · Abschnitt 4.5 · PDF-Seite 8
HOS-142732 · Präparat HOS-098862
Fluticasone propionate and salmeterol are both poor substrates of P-glycoprotein (P-gp). Fluticasone did not
show P-gp inhibition potential in in vitro studies. No information is available on salmeterol P-gp inhibition
potential. No clinical pharmacology studies with a specific P-gp inhibitor and fluticasone
propionate/salmeterol have been conducted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propionate (HOS-108915)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-01T11:08:00Z · SHA-256 f36f045aa8120c0652f1b30e2fc29bd85c6b0a5d5a72000932bdbf16074e536b · Passage 82e8fbc7f66f29f6bd9e7a3fedc24831c92c1c5d3189adad3cbef4ee31cd67b0 · Zeichen 4067–4419 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.